GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose

Phase 1

Completed

Conditions: Inflammation
Arthritis, Rheumatoid

First Posted Date: 2007-02-26

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 16

Registration Number: NCT00439881

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809

Phase 1

Completed

Conditions: Substance Dependence

Interventions: Drug: GSK598809
Drug: Placebo
Drug: Caffeine

First Posted Date: 2007-02-21

Last Posted Date: 2017-07-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 104

Registration Number: NCT00437632

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809

Phase 1

Completed

Conditions: Substance Dependence

Interventions: Drug: GSK598809
Drug: Placebo

First Posted Date: 2007-02-21

Last Posted Date: 2017-08-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00437840

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

Brain Metastases In ErbB2-Positive Breast Cancer

Phase 2

Terminated

Conditions: Neoplasms, Breast

Interventions: Drug: capecitabine
Drug: topotecan
Drug: lapatinib

First Posted Date: 2007-02-19

Last Posted Date: 2015-10-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 22

Registration Number: NCT00437073

Locations: 🇸🇪
GSK Investigational Site, Uppsala, Sweden

Odiparcil QT Definitive Study

Phase 1

Terminated

Conditions: Fibrillation, Atrial
Atrial Fibrillation

First Posted Date: 2007-02-19

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 54

Registration Number: NCT00437242

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus

Phase 2

Terminated

Conditions: Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2

First Posted Date: 2007-02-19

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT00437164

Locations: 🇺🇸
GSK Investigational Site, Beverly Hills, California, United States

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

Phase 1

Completed

Conditions: Nausea and Vomiting, Chemotherapy-Induced

Interventions: Drug: Casopitant (GW679769) Oral Tablets
Drug: dexamethasone
Drug: ondansetron

First Posted Date: 2007-02-19

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 37

Registration Number: NCT00437229

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Implementing Hospital-based Active Surveillance Procedures for Vaccine Safety Monitoring at IMSS Hospitals in Mexico

Completed

Conditions: Intussusception
LRTI-related Post Neonatal Deaths

First Posted Date: 2007-02-19

Last Posted Date: 2011-01-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 134

Registration Number: NCT00436358

Locations: 🇲🇽
GSK Investigational Site, Mexico DF, Mexico

Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)

Phase 3

Terminated

Conditions: Analgesia

Interventions: Drug: Propofol
Drug: Remifentanil

First Posted Date: 2007-02-19

Last Posted Date: 2017-05-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 39

Registration Number: NCT00436345

Locations: 🇮🇹
GSK Investigational Site, Palermo, Sicilia, Italy

To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug

Completed

Conditions: Healthy Subjects

First Posted Date: 2007-02-19

Last Posted Date: 2008-10-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT00436228

Locations: 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy